The revised EBM catalog came into force in Germany in July 2022

22

Jul 2022

The reimbursement of services in the public outpatient sector in Germany is regulated in the EBM catalog (Einheitlicher Bewertungsmaßstab), updated once a quarter (4 times a year). The adaption time frame of the EBM catalog for a specific code is around five years but varies depending on the evidence. The latest EBM (German Uniform Evaluation Standard) catalog came into force on July 1, 2022.

The most significant changes concern introducing and updating multiple EBM codes for IVD tests and adjusting tariffs and content of radiotherapy services.

The examples of the new codes in the IVD field introduced in the EBM catalog:

  • 01870 "Prenatal analysis of fetal DNA from maternal blood for the presence of trisomy 13, 18 or 21 in line with the guidelines of the Federal Joint Committee on medical care during pregnancy and after childbirth (Maternity Directive)" with a tariff of €184.99;
  • 32701 "Detection of Clostridioides difficile in the stool" (bacteriological examination) with a tariff of €23.80;
  • 32702 "Surcharge for the code 32701 for the nucleic acid detection of Clostridioides difficile in the case of discordant immunoassay results" with a tariff of €19.90;
  • 32777 "Semi-quantitative European Committee on Antimicrobial Susceptibility Testing (EUCAST) or Clinical and Laboratory Standards Institute (CLSI) selected susceptibility testing of clinically relevant bacteria grown in pure culture from a material with atypical Gram staining characteristics or for which EUCAST or CLSI has defined service content other than code 32772 or 32773" with a tariff of €6.93;
  • 32851 "Nucleic acid detection of one or more of the pathogens for acute respiratory infections (reporting of findings within 24 hours of receipt of material in the laboratory)" with a tariff of €19.90. The considered pathogens include viral pathogens: influenza A and B, parainfluenza viruses, bocavirus, respiratory syncytial virus, adenoviruses, human metapneumovirus, rhinoviruses, enteroviruses, and coronaviruses (except beta-coronavirus SARS-CoV-2); bacterial pathogens: Bordetella pertussis and B. parapertussis, Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophilia, Streptococcus pneumoniae, Haemophilus influenzae;
  • 32852 "Nucleic acid detection of one or more of the pathogens of sexually transmitted infections (findings to be reported within 24 hours of receipt of material in the laboratory) with a tariff of €19.90. The considered pathogens include Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Trichomonas vaginalis, Herpes simplex virus types 1 and 2;
  • 32853 "Nucleic acid detection of one or more of the pathogens of acute gastrointestinal infections (findings to be reported within 24 hours of receipt of material in the laboratory)" with a tariff of €19.90. The considered pathogens include viral pathogens: noroviruses, enteroviruses, rotaviruses, adenoviruses, astroviruses, sapoviruses; bacterial pathogens: campylobacter, salmonella, shigella, Yersinia enterocolitica, Yersinia pseudotuberculosis, Enterohemorrhagic Escherichia coli (EHEC)/Enteropathogenic Escherichia coli (EPEC); Cryptosporidium spp., Entamoeba histolytica, Giardia duodenalis, Strongyloides spp.

The full details in German can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

11

Aug 2022

The French National Authority for Health released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies in July 2022. Twenty recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services. Opinions concern cardiovascular and peripheral vascular, neurovascular and neuromodulation, orthopedic, endocrine, and ENT devices, as well as breast implants and medical aids. Except for this, CNEDiMTS published two positive and two negative opinions concerning transitional coverage of devices.

Read more

10

Aug 2022

In July 2022, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (transcatheter tricuspid valve annuloplasty for tricuspid regurgitation, and transcatheter tricuspid valve leaflet repair for tricuspid regurgitation), one new Diagnostic Guidance (PLGF-based testing to help diagnose suspected preterm pre-eclampsia), and four new Medtech Innovation Briefings (ProciseDx point-of-care platform for IBD, RespiraSense for continuously monitoring respiratory rate, Lenus COPD Support Service, and cyanoacrylate glue for hernia mesh fixation). Also, five clinical guidelines were updated.

Read more

09

Aug 2022

In May-July 2022, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers.

Read more

05

Aug 2022

In July 2022, Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) announced the extension of temporary reimbursement for gene expression profile (GEP) testing for early-stage breast cancer detection until December 31, 2022, and for molecular biology tests by next-generation sequencing (NGS) until June 30, 2023.

Read more

03

Aug 2022

On June 27, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) published the determined funding priorities for healthcare research projects (seven topics) and clinical guidelines (four topics).

Read more